What is Vesalius?
Vesalius Longevity Labs operates at the intersection of biotechnology and preventative health, distinguishing itself as the first publicly traded entity exclusively dedicated to the advancement of peptide science. The company utilizes a sophisticated B2Doctor distribution model, providing licensed healthcare practitioners with access to high-efficacy regenerative treatments. By focusing on the biological mechanisms of healthspan and vitality, Vesalius bridges the gap between clinical research and practical wellness applications, positioning itself as a critical infrastructure provider for the burgeoning longevity market.
How much funding has Vesalius raised?
Vesalius has raised a total of $6.9M across 2 funding rounds:
Stock/Share Issuance
$168K
Stock/Share Issuance
$6.7M
Stock/Share Issuance (2025): $168K, investors not publicly disclosed
Stock/Share Issuance (2026): $6.7M, investors not publicly disclosed
Key Investors in Vesalius
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Vesalius?
With the recent influx of capital, Vesalius is poised to accelerate its research and development pipeline, focusing on the clinical validation of new peptide compounds. The strategic deployment of these funds will likely prioritize the expansion of its global distribution network and the enhancement of its digital health platform. As the company matures, the focus will shift toward deepening its market penetration among healthcare providers and establishing new benchmarks for safety and efficacy in the peptide therapy space. This growth phase is expected to solidify the company's status as a dominant force in the regenerative medicine landscape, leveraging its public market status to drive long-term shareholder value and scientific innovation.
See full Vesalius company page
